Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

193.61 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Oct 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about AbbVie

< Previous 1 2 3 4 5 6 7 8 9 Next >
Active Biotech Alert: FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:ABBV),(NASDAQ:BGNE),(NASDAQ:HCM),(NASDAQ:ELVN) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
Via Investor Brand Network
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
EQNX::TICKER_START (NYSE:ANVS),(NYSE:LLY),(NYSE:PFE),(NYSE:NVO),(NASDAQ:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
AbbVie Stock Post Humira is Still an Attractive Stock to Hold
AbbVie's strategic diversification and strong financial position make it possible to sustain growth despite the perceived “Humira cliff.” 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:NVAX),(NASDAQ:RGNX),(NASDAQ:BNTX),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
3 Best Growth Stocks to Own for the Next 10 Years
When in doubt, zoom out; these three growth stocks have a history of strong performance that is likely to continue for the next 10 years 
Via MarketBeat
Topics Economy
Exposures Economy
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
From FN Media Group LLC
Via GlobeNewswire
Lock in Gains: 3 Dividend Stocks Poised to Boost Payouts Soon
These three stocks have a long history of increasing their dividends and are likely to benefit from sector rotation on expectations of lower interest rates 
Via MarketBeat
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Economy
As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032
EQNX::TICKER_START (NYSE:OGEN),(NYSE:ABT),(NASDAQ:BIIB),(NYSE:PFE),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
Revolutionary Magnetic Therapy Could Speed Up Bipolar Treatment
New research suggests that powerful magnets could effectively treat bipolar disorder. This therapy, which is known as accelerated intermittent theta burst stimulation (iTBS), uses magnetic waves... 
Via PressReach
Exposures Product Safety
AbbVie Analysts Lead the Stock Higher as Humira Worries Recede
AbbVie had a solid quarter, accelerating growth and giving positive guidance that has analysts lifting their price targets and the stock advancing. 
Via MarketBeat
Topics Earnings Intellectual Property
Exposures Financial Intellectual Property
Pharma Stock Cuts Earnings Outlook: Still a Buying Opportunity
Merck stock is down more than 4% after lowering its 2024 earnings outlook, but if you look beyond the headline numbers, this could be a chance to buy the dip 
Via MarketBeat
Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)
From Alector, Inc.
Via GlobeNewswire
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
EQNX::TICKER_START (NASDAQ:TNXP),(NYSE:PFE),(NYSE:LLY),(NYSE:ABBV),(NASDAQ:AXSM) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
From FN Media Group LLC
Via GlobeNewswire
Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
Drug prices continue to rise, driving up healthcare costs. Pharmaceutical companies usually hike drug prices at the beginning of each year. In January 2024 
Via MarketBeat
MarketBeat Week in Review – 7/1 - 7/5
The market was mostly quiet in a holiday-shortened week; that may change next week with the latest inflation readings and the kickoff of a new earnings season 
Via MarketBeat
Topics Economy
Exposures Interest Rates
AbbVie Stock: A Perfect Dip for Investors to Buy
ABBV stock is down over 3% to start the second half of the year; the stock may be overvalued in the short term but still offers value for long-term investors 
Via MarketBeat
Topics ETFs
Investing in Biotech: High Risk for a Potentially High Reward
Biotech is an exciting and promising area, and investors with some patience, the stomach for volatility, and a high risk tolerance can potentially benefit. 
Via MarketBeat
2 Generic Drug Makers With Growing Runways
Brand name drug costs continue to climb but patients and insurers find respite by migrating to generic or biosimilar versions as patents run out. 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:RENB),(NASDAQ:CYTO),(NYSE:PFE),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Exposures Death
AbbVie Tracking for New Highs in 2024
Future Dividend King AbbVie is tracking for new highs as the shift away from Humira-based business gains momentum with new treatments and acquisitions. 
Via MarketBeat
Topics Earnings
Exposures Financial
MarketBeat Week in Review – 4/29 - 5/3
Apple, Amgen, and a weak jobs report helped move the market higher as investors temporarily looked past the possibility of no interest rate cuts in 2024 
Via MarketBeat
Topics Economy Stocks
Exposures Interest Rates US Equities
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032
From FN Media Group LLC
Via GlobeNewswire
Analyst Sentiment, Revenue Growth Will Lead AbbVie Stock Higher
After falling nearly 6% based on concerns about Humira sales, AbbVie stock is recovering, and bullish analyst sentiment is likely to push the stock higher 
Via MarketBeat
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AdTheorent Holding Company, Inc. (Nasdaq – ADTH), Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN)
From Brodsky & Smith LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Kinnate Biopharma Inc. (Nasdaq – KNTE)
From Brodsky & Smith LLC
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.